ReviewFrontiers in human neuroscience2024
Cognitive dysfunction in Moyamoya disease: latest developments and future directions.
Review in Frontiers in human neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Chinese expert consensus on the treatment and diagnosis of moyamoya disease and moyamoya syndrome (2024).Stroke and vascular neurology · 2026Article
- Choroid plexus enlargement correlates with cognitive dysfunction and disease progression in Moyamoya disease.Neurosurgical review · 2025Article
- Indirect Revascularization for Pediatric Moyamoya Angiopathy: Insights from a Brazilian Cohort.Journal of clinical medicine · 2025Article
- Multisystemic Impact of RNF213 Arg4810Lys: A Comprehensive Review of Moyamoya Disease and Associated Vasculopathies.International journal of molecular sciences · 2025Review
- Disrupted resting-state interhemispheric functional connectivity in patients with first-episode moyamoya disease.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive dysfunction is common in Moyamoya disease (MMD). However, current knowledge of cognitive impairment in MMD is inadequate. In this review, we explored the characteristics of altered cognitive function associated with MMD and offered recommendations aimed at guiding potential research endeavors into the cognitive dysfunction in MMD. Cognitive functions, including executive function, intelligence, memory and so on, show characteristic declines in MMD. The effects of cerebral revascularization surgery on cognitive impairment are controversial. Currently, there is still a lack of relevant research on cognitive impairment. Research on the pathogenesis and etiology associated with Moyamoya disease as well as long-term cohort studies, are important future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.